137 related articles for article (PubMed ID: 9381706)
1. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
[TBL] [Abstract][Full Text] [Related]
2. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
Kolygin BA
Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558
[No Abstract] [Full Text] [Related]
3. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
4. Doxorubicin-induced cardiomyopathy.
Muggia FM; Speyer JL
N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
[No Abstract] [Full Text] [Related]
5. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
7. [Cardioxane in pediatric oncohematology].
Kurmashov VI; Gavrilova IE; Maiakova SA; Popa AV; Morozova OV; Ivanova LF; Kurdiukov BV; Gavrikova NV; Il'iashenko VV; Terzich M
Vopr Onkol; 1997; 43(4):456-9. PubMed ID: 9381705
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-induced myocardial injury.
Fujisaki G; Inokuchi C; Murashige N
N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
[No Abstract] [Full Text] [Related]
9. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
[TBL] [Abstract][Full Text] [Related]
11. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
[TBL] [Abstract][Full Text] [Related]
12. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
13. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
[No Abstract] [Full Text] [Related]
14. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
15. [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].
Sauer H
Strahlenther Onkol; 1997 Jan; 173(1):51-2. PubMed ID: 9082586
[No Abstract] [Full Text] [Related]
16. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline cardiotoxicity in children.
Kremer LC; Caron HN
N Engl J Med; 2004 Jul; 351(2):120-1. PubMed ID: 15247351
[No Abstract] [Full Text] [Related]
18. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
19. Strategies for reduction of anthracycline cardiac toxicity.
Speyer J; Wasserheit C
Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
[TBL] [Abstract][Full Text] [Related]
20. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
